Aurinia Pharmaceuticals Inc (AUPH)vsRegeneron Pharmaceuticals Inc (REGN)
AUPH
Aurinia Pharmaceuticals Inc
$16.44
-0.93%
HEALTHCARE · Cap: $2.21B
REGN
Regeneron Pharmaceuticals Inc
$788.04
-1.00%
HEALTHCARE · Cap: $82.55B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 4887% more annual revenue ($15.53B vs $311.51M). AUPH leads profitability with a 100.8% profit margin vs 27.9%. AUPH trades at a lower P/E of 7.3x. AUPH earns a higher WallStSmart Score of 67/100 (B-).
AUPH
Strong Buy67
out of 100
Grade: B-
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AUPH.
Margin of Safety
+43.2%
Fair Value
$1400.68
Current Price
$788.04
$612.64 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 101 of every $100 in revenue as profit
Strong operational efficiency at 55.7%
Earnings expanding 75.5% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
No major concerns identified
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 100.8% and operating margin at 55.7%. Revenue growth of 18.9% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : AUPH
No major red flags identified for AUPH, but monitor valuation.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
AUPH carries more volatility with a beta of 1.41 — expect wider price swings.
AUPH is growing revenue faster at 18.9% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AUPH scores higher overall (67/100 vs 66/100), backed by strong 100.8% margins and 18.9% revenue growth. REGN offers better value entry with a 43.2% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?